Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An ambispective, real world, multicenter, longitudinal, phase IV study evaluating effectiveness and safety of Talazoparib in patients with locally advanced or metastatic HER2- BC, with somatic or germline BRCA mutation (sBRCA or gBRCA)

Next Previous
Search
Trial Profile

An ambispective, real world, multicenter, longitudinal, phase IV study evaluating effectiveness and safety of Talazoparib in patients with locally advanced or metastatic HER2- BC, with somatic or germline BRCA mutation (sBRCA or gBRCA)

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 09 Feb 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Talazoparib (Primary)
  • Indications Advanced breast cancer; HER2 negative breast cancer; Male breast cancer
  • Focus Therapeutic Use
  • Acronyms ViTAL

    • Most Recent Events

    • 10 Dec 2022 Results of cohort 1 assessing (n=86; From November 2018 to May 2021) to ensure the effectiveness and safety of TALA in real-lifesetting among patients with locally advanced or metastatic HER2-breast cancer, with somaticor germline BRCA1/2 mutation, presented at the 45th Annual San Antonio Breast Cancer Symposium.
    • 10 Dec 2022 Results of cohort 2 assessing (n=85; From November 2018 to May 2021) to ensure the effectiveness and safety of Talazoparib in the real-world setting among patients with locally advanced or metastatic HER2-breast cancer, with somatic or germline BRCA1/2 mutation, presented at the 45th Annual San Antonio Breast Cancer Symposium.
    • 15 Feb 2022 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top